Trial Profile
Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Therapeutic Use
- 19 Dec 2012 Planned End Date changed from 1 Dec 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 23 Jun 2009 New trial record